5.13
-0.15 (-2.84%)
| Penutupan Terdahulu | 5.28 |
| Buka | 5.11 |
| Jumlah Dagangan | 1,508,369 |
| Purata Dagangan (3B) | 1,157,966 |
| Modal Pasaran | 479,696,928 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.08 |
| Harga / Jualan (P/S) | 0.520 |
| Harga / Buku (P/B) | 1.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | -12.20% |
| Margin Operasi (TTM) | -14.80% |
| EPS Cair (TTM) | -1.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.36% |
| Nisbah Semasa (MRQ) | 1.90 |
| Aliran Tunai Operasi (OCF TTM) | -6.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 18.68 M |
| Pulangan Atas Aset (ROA TTM) | -5.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -13.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Myriad Genetics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -2.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.77% |
| % Dimiliki oleh Institusi | 104.21% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Camber Capital Management Lp | 30 Jun 2025 | 2,000,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 6.00 (Wells Fargo, 16.96%) | Pegang |
| 6.00 (UBS, 16.96%) | Pegang | |
| Median | 6.00 (16.96%) | |
| Purata | 6.00 (16.96%) | |
| Jumlah | 2 Pegang | |
| Harga Purata @ Panggilan | 4.43 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 24 Feb 2026 | 6.00 (16.96%) | Pegang | 4.43 |
| Wells Fargo | 24 Feb 2026 | 6.00 (16.96%) | Pegang | 4.43 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DONNELLY BRIAN J | 4.85 | - | 226,804 | 1,099,999 |
| FOX JENNIFER LYNNE | 4.85 | 4.66 | 189,881 | 922,062 |
| HAAS KEVIN RICHARD | - | 4.66 | -22,310 | -103,965 |
| MUZZEY DALE | 4.85 | 4.66 | 135,397 | 663,857 |
| RAHA SAMRAAT S. | 4.85 | 4.66 | 571,437 | 2,780,422 |
| SOLAIMAN SHEREEN | 4.85 | 4.66 | 158,513 | 771,578 |
| VERRATTI MARK | 4.85 | 4.66 | 218,134 | 1,063,515 |
| WHEELER BENJAMIN RICHARD | 4.85 | 4.66 | 201,434 | 977,858 |
| Jumlah Keseluruhan Kuantiti Bersih | 1,679,290 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 8,175,327 | |||
| Purata Pembelian Keseluruhan ($) | 4.85 | |||
| Purata Jualan Keseluruhan ($) | 4.66 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WHEELER BENJAMIN RICHARD | Pegawai | 15 Mar 2026 | Dibuang (-) | 3,069 | 4.66 | 14,302 |
| VERRATTI MARK | Pegawai | 15 Mar 2026 | Dibuang (-) | 14,707 | 4.66 | 68,535 |
| MUZZEY DALE | Pegawai | 15 Mar 2026 | Dibuang (-) | 16,732 | 4.66 | 77,971 |
| HAAS KEVIN RICHARD | Pegawai | 15 Mar 2026 | Dibuang (-) | 11,737 | 4.66 | 54,694 |
| RAHA SAMRAAT S. | Pegawai | 14 Mar 2026 | Dibuang (-) | 10,816 | 4.66 | 50,403 |
| WHEELER BENJAMIN RICHARD | Pegawai | 14 Mar 2026 | Dibuang (-) | 1,097 | 4.66 | 5,112 |
| VERRATTI MARK | Pegawai | 14 Mar 2026 | Dibuang (-) | 5,418 | 4.66 | 25,248 |
| SOLAIMAN SHEREEN | Pegawai | 14 Mar 2026 | Dibuang (-) | 5,784 | 4.66 | 26,953 |
| MUZZEY DALE | Pegawai | 14 Mar 2026 | Dibuang (-) | 8,288 | 4.66 | 38,622 |
| HAAS KEVIN RICHARD | Pegawai | 14 Mar 2026 | Dibuang (-) | 4,161 | 4.66 | 19,390 |
| RAHA SAMRAAT S. | Pegawai | 13 Mar 2026 | Dibuang (-) | 36,304 | 4.66 | 169,177 |
| WHEELER BENJAMIN RICHARD | Pegawai | 13 Mar 2026 | Dibuang (-) | 586 | 4.66 | 2,731 |
| VERRATTI MARK | Pegawai | 13 Mar 2026 | Dibuang (-) | 9,164 | 4.66 | 42,704 |
| FOX JENNIFER LYNNE | Pegawai | 13 Mar 2026 | Dibuang (-) | 5,995 | 4.66 | 27,937 |
| SOLAIMAN SHEREEN | Pegawai | 13 Mar 2026 | Dibuang (-) | 8,899 | 4.66 | 41,469 |
| MUZZEY DALE | Pegawai | 13 Mar 2026 | Dibuang (-) | 12,779 | 4.66 | 59,550 |
| HAAS KEVIN RICHARD | Pegawai | 13 Mar 2026 | Dibuang (-) | 6,412 | 4.66 | 29,880 |
| RAHA SAMRAAT S. | Pegawai | 12 Mar 2026 | Diperolehi (+) | 618,557 | 4.85 | 3,000,001 |
| WHEELER BENJAMIN RICHARD | Pegawai | 12 Mar 2026 | Diperolehi (+) | 206,186 | 4.85 | 1,000,002 |
| DONNELLY BRIAN J | Pegawai | 12 Mar 2026 | Diperolehi (+) | 226,804 | 4.85 | 1,099,999 |
| VERRATTI MARK | Pegawai | 12 Mar 2026 | Diperolehi (+) | 247,423 | 4.85 | 1,200,002 |
| FOX JENNIFER LYNNE | Pegawai | 12 Mar 2026 | Diperolehi (+) | 195,876 | 4.85 | 949,999 |
| SOLAIMAN SHEREEN | Pegawai | 12 Mar 2026 | Diperolehi (+) | 173,196 | 4.85 | 840,001 |
| MUZZEY DALE | Pegawai | 12 Mar 2026 | Diperolehi (+) | 173,196 | 4.85 | 840,001 |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data |
| 12 Jan 2026 | Pengumuman | Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance |
| 05 Jan 2026 | Pengumuman | Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |